FA
Fagron N.V.
FAGR.BR · BRU
21.80 € -1.80% (-0.40 €)
1M -1.79%
Market Cap 1.63B €
P/E Ratio 17.93x
Div. Yield 1.26%
ROE 16.94%
Bulios Fair Price
31.31 €
43.6% upside
Current Price
21.8 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, FAGR.BR is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
76 /100
Cheap P/E 17.93x
PEG 1.38x
EV/EBITDA 10.17x
Growth
65 /100
Stable EPS growth 8.91%
Book val. growth 11.06%
Rev. growth 11.66%
Profitability
58 /100
Moderate Gross margin 15.25%
FCF margin 11.87%
Net margin 9.56%
Quality
68 /100
Excellent ROIC 10.99%
Asset turnover 0.77x
ROE 16.94%
Debt
66 /100
Moderate Debt/Equity 0.93x
Net debt/EBITDA 1.70x
Current ratio 2.11x
Stability
86 /100
Stable Beta 0.38x
Profitable years 6
Rev. volatility 2.54%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FAGR.BR
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Rafael Padilla
Employees
4,880
Headquarters
Nazareth
Upcoming events
18 FEB
Earnings
Upcoming earnings report